Editas Medicine receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Editas Medicine Inc (EDIT)
Editas Medicine Inc stock price live, this page displays NASDAQ EDIT stock exchange data. View the EDIT premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Editas Medicine Inc real time stock price chart below.
What Is the Editas Medicine Inc Stock Price Today?
The Editas Medicine Inc stock price today is 3.41.
What Is the Stock Symbol for Editas Medicine Inc?
The stock ticker symbol for Editas Medicine Inc is EDIT.
Is EDIT the Same as $EDIT?
$EDIT is a common way to refer to the Editas Medicine Inc ticker symbol in social media, forums, and online discussions. The dollar sign is a shorthand convention used to indicate that it is a stock ticker symbol
What Stock Exchange Does Editas Medicine Inc Trade On?
Editas Medicine Inc is listed and trades on the NASDAQ stock exchange.
Is Editas Medicine Inc a Good Stock to Buy?
Determining whether Editas Medicine Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess the current Editas Medicine Inc share price compared with the fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the EDIT quote. (ISIN: US28106W1036)
What Is the Editas Medicine Inc Stock Price Today?
The Editas Medicine Inc stock price today is 3.41.
What Is the Stock Symbol for Editas Medicine Inc?
The stock ticker symbol for Editas Medicine Inc is EDIT.
Is EDIT the Same as $EDIT?
$EDIT is a common way to refer to the Editas Medicine Inc ticker symbol in social media, forums, and online discussions. The dollar sign is a shorthand convention used to indicate that it is a stock ticker symbol
What Stock Exchange Does Editas Medicine Inc Trade On?
Editas Medicine Inc is listed and trades on the NASDAQ stock exchange.
Is Editas Medicine Inc a Good Stock to Buy?
Determining whether Editas Medicine Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess the current Editas Medicine Inc share price compared with the fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the EDIT quote. (ISIN: US28106W1036)
Currency in USD
3.41
+0.02(+0.59%)
Real-time Data·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
3.37
3.58
52 wk Range
1.23
4.54
EDIT is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
3.373.58
52 wk Range
1.234.54
Key Statistics
Edit
Prev. Close
Open
Volume
Average Vol. (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Vol. (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
EDIT Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Price Target
5.72
Upside
+67.81%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
2 analysts have revised their earnings upwards for the upcoming period
- Form 8K Editas Medicine For: 7 April
- Investing.com
- Editas Medicine receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Form 8K Editas Medicine For: 7 April
- Investing.com
- Editas Medicine receives Investment Bank Analyst Rating Update
- Investing.com
Pro
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. Its lead program is EDIT-401, a one-time therapy designed to reduce LDL cholesterol through the upregulation of the LDL receptor to treat hyperlipidemia. The company also develops therapies to treat Sickle cell disease and transfusion-dependent beta thalassemia; and in vivo gene editing medicines indicated for other cells and tissues. It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors, and autoimmune disease. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.
Editas Medicine Inc SWOT Analysis
Market Valuation | Analysts set price targets ranging from $3 to $5, reflecting varied perspectives on Editas' potential in the competitive gene editing landscape |
Pipeline Progress | Delve into Editas' strategic focus on cardiometabolic diseases, with plans for IND and CTA submissions by mid-2026 and proof-of-concept data by end-2026 |
Financial Fortitude | Explore Editas' solid financial foundation, with a cash runway extending to Q2 2027, supporting ambitious R&D efforts despite projected losses |
Gene Editing Pionee | Editas Medicine leads in cardiometabolic gene therapies, with EDIT-401 showing potential for 90% LDL-C reduction, outperforming current treatments |
Compare EDIT to Peers and Sector
Metrics to compare | EDIT | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipEDITPeersSector | |
|---|---|---|---|---|
P/E Ratio | −2.1x | −1.9x | −0.5x | |
PEG Ratio | −0.06 | −0.09 | 0.00 | |
Price / Book | 12.4x | 2.1x | 2.6x | |
Price / LTM Sales | 8.3x | 68.8x | 3.2x | |
Upside (Analyst Target) | 45.3% | 388.3% | 47.6% | |
Fair Value Upside | Unlock | 8.0% | 6.1% | Unlock |
Analyst Ratings
7 Buy
5 Hold
2 Sell
Ratings:
14 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 5.72
(+67.81% Upside)
Earnings
Latest Release
Mar 09, 2026
EPS / Forecast
-0.06 / -0.23
Revenue / Forecast
24.74M / 8.02M
People Also Watch
FAQ
What Is the Editas Medicine (EDIT) Stock Price Today?
The Editas Medicine stock price today is 3.41 USD.
What Stock Exchange Does Editas Medicine Trade On?
Editas Medicine is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Editas Medicine?
The stock symbol for Editas Medicine is "EDIT."
What Is the Editas Medicine Market Cap?
As of today, Editas Medicine market cap is 333.74M USD.
What Is Editas Medicine's Earnings Per Share (TTM)?
The Editas Medicine EPS (TTM) is -1.80.
When Is the Next Editas Medicine Earnings Date?
Editas Medicine will release its next earnings report on May 06, 2026.
From a Technical Analysis Perspective, Is EDIT a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has Editas Medicine Stock Split?
Editas Medicine has split 0 times.
How Many Employees Does Editas Medicine Have?
Editas Medicine has 87 employees.
What is the current trading status of Editas Medicine (EDIT)?
As of Apr 15, 2026, Editas Medicine (EDIT) is trading at a price of 3.41 USD, with a previous close of 3.39 USD. The stock has fluctuated within a day range of 3.37 USD to 3.58 USD, while its 52-week range spans from 1.23 USD to 4.54 USD.
What Is Editas Medicine (EDIT) Price Target According to Analysts?
The average 12-month price target for Editas Medicine is 5.72 USD, with a high estimate of 15 USD and a low estimate of 1 USD. 7 analysts recommend buying the stock, while 2 suggest selling, leading to an overall rating of Buy. The stock has an +67.81% Upside potential.
What Is the EDIT Premarket Price?
EDIT's last pre-market stock price is 3.32 USD. The pre-market share volume is 2,730.00, and the stock has decreased by -0.07, or -2.06%.
What Is the EDIT After Hours Price?
EDIT's last after hours stock price is 3.28 USD, the stock has decreased by -0.11, or -3.24%.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.